Omega-3 ethyl esters (fish oil, e.g. Lovaza or Vascepa)
All patients should receive general measures (ie, address modifiable causes, manage atherosclerotic cardiovascular disease [ASCVD] risk, implement lifestyle modification [eg, dietary changes, reduction in alcohol consumption]) and optimal low-density lipoprotein lowering therapy for 4 to 12 weeks before considering triglyceride lowering therapy. For patients whose triglycerides remain ≥500 mg/dL and who do not warrant icosapent ethyl for additional ASCVD risk reduction, any prescription strength omega-3 fatty acid (including icosapent ethyl) or a fibrate (fenofibrate preferred) is reasonable.
No, Lovaza and Vascepa are not the same. They are distinct prescription omega-3 fatty acid formulations with different compositions and, importantly, different FDA-approved indications.
Lovaza (omega-3-acid ethyl esters USP) contains both EPA and DHA as ethyl esters, with approximately 465 mg of EPA and 375 mg of DHA per 1-gram capsule. [1] In contrast, Vascepa (icosapent ethyl) contains only highly purified EPA as an ethyl ester, providing 1 gram of EPA per capsule with essentially no DHA. [2-3]
The most clinically significant difference lies in their FDA-approved indications. Both are approved as adjuncts to diet for reducing triglyceride levels in adults with severe hypertriglyceridemia (≥500 mg/dL). [1-2][4] However, Vascepa has an additional cardiovascular outcomes indication based on the REDUCE-IT trial: it is approved to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina in patients with elevated triglycerides (≥150 mg/dL) who are on maximally tolerated statin therapy and have either established cardiovascular disease or diabetes with additional risk factors. [2][4-5] Lovaza does not have this cardiovascular risk reduction indication. [1]
Their lipid effects also differ. While both lower triglycerides substantially, Lovaza increases LDL-C by approximately 45% in patients with severe hypertriglyceridemia, whereas Vascepa decreases LDL-C by approximately 6.5%. [2] This distinction may be clinically relevant when selecting therapy for patients with mixed dyslipidemia.
The standard dosing is 4 grams daily for both medications, typically administered as 2 grams twice daily with food. [1][4]
